Jyong Biotech (MENS) Long-Term Deferred Tax (2024)

Jyong Biotech's (MENS) quarterly Long-Term Deferred Tax came in at $934000.0 in Q4 2024.

Jyong Biotech (MENS) Long-Term Deferred Tax (2024) Analysis & Trends

Jyong Biotech's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $934000.0 for Q4 2024.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $934000.0 in Q4 2024; TTM through Dec 2024 was $934000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $934000.0, changed N/A from the prior year.
Long-Term Deferred Tax steadied at $934000.0 in Q4 2024 per MENS's latest filing.
Across five years, Long-Term Deferred Tax topped out at $934000.0 in Q4 2024 and bottomed at $934000.0 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Jyong Biotech	197.86 Mn	197.86 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	934,000.00